Skip Navigation

Journal of Intellectual Property Law & Practice 2008 3(11):692-694; doi:10.1093/jiplp/jpn174
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sellars, C.
Right arrow Articles by Easey, A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Current Intelligence

First successful legal challenge to NICE guidance

Clare Sellars
Counsel, IPM&T Group, McDermott,
Will & Emery UK LLP

Amanda Easey
Associate, IPM&T Group, McDermott,
Will & Emery UK LLP

R (on the application of Eisai Ltd) (Claimant) v National Institute For Health & Clinical Excellence; Shire Pharmaceuticals Ltd and Association of the British Pharmaceutical Industry (Interveners) (2008) EWCA Civ 438, 1 May 2008

The Court of Appeal ruled that the procedure undertaken by the National Institute for Health and Clinical Excellence (NICE) before issuing guidance on the use of certain drugs for the treatment of Alzheimer's Disease (AD) was procedurally unfair.

Correspondence: Email: csellars{at}europe.mwe.com

Correspondence: Email: aeasey{at}europe.mwe.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.